ArticleDiscover nano2026
Exploring the bioactive potential of green synthesized silver nanoparticles coated serratiopeptidase and chalcone derivatives.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerratiopeptidase is a proteolytic enzyme that has gained considerable interest in the medical and pharmaceutical industries due to its analgesic, fibrinolytic, and anti-inflammatory effects. Silver nanoparticles (AgNPs) were coated on Serratiopeptidase to analyze and compare its bioactivity along with the bioactivity of newly synthesized chalcone derivatives.
resultsIn the present study, two novel chalcone derivatives were successfully synthesized and evaluated for their biological activities. Among the synthesized compounds, VIT-A3S exhibited the highest proteolytic activity (231.63 ± 0.43 U/mL) and anti-inflammatory activities (92.67 ± 0.48%), indicating its therapeutic potential. The structural elucidation of VIT-A3S was carried out using spectroscopic techniques, including Nuclear Magnetic Resonance (NMR), Fourier Transform Infrared Spectroscopy (FTIR), and Ultraviolet-Visible (UV-Vis) spectroscopy, confirming its molecular architecture. Furthermore, silver nanoparticles (Ag NPs) were synthesized and characterized, with their colloidal stability assessed using zeta potential analysis. The integrated approach combining synthetic chemistry, biological evaluation and nanotechnology highlighted the potential of VIT-A3S for further pharmaceutical development. Overall, the study highlighted that the chalcone derivatives (VIT-A3S and VIT-PAGS) possessed a broad spectrum of biological activities including antioxidant, anti-inflammatory, and protease functions, with significantly higher potency compared to serratiopeptidase based formulations.
conclusionThese findings suggest that chalcone derivatives represent a promising class of therapeutic agents, with potential application in the management of inflammation-related disorders and warrant further in-depth pharmacological and clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.